December 20, 2021 — Immunolight LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it is now recruiting patients for a phase 1 study of its X-PACT Cancer Treatment system in Breast, Melanoma, Sarcoma and Head and Neck Cancers, to be conducted at Duke University Medical Center.
The heart of the X-PACT system is 8-MOP (also known as 8-methoxypsoralen or methoxsalen) which has been successfully used for decades in the treatment of autoimmune disease, skin disorders and certain skin and blood cancers. However, since UV light, which is needed to activate 8-MOP, cannot penetrate through tissue, it has not been possible to use 8-MOP to treat solid tumors. Immunolight's X-PACT system solves this problem. Innovative Immunolight phosphor materials convert tissue penetrating energies, such as low dose X-ray, into UV light inside solid tumors in the body. These energy converting phosphors are injected along with 8-MOP into the solid tumor, and low dose x-ray energy is applied at the site. The phosphors convert the x-ray into UV light which activates the 8-MOP inside the solid tumor to kill the cancer.
More details about the Phase 1 trial and eligibility criteria can be found here.
Immunolight founder and CEO Rick Bourke commented, "We are thrilled to start patient recruitment and begin this Phase 1 trial, bringing our innovative technology to fruition in treating cancer and starting what we believe is a new era in cancer treatment."
This milestone is the culmination of over 13 years of intense research and development in partnership with Duke University and Duke Medical Center where a team of over 30 scientists, physicians and engineers has been active. "From day one, our highest priority has been to translate this amazing science into a paradigm changing cancer treatment in patients," President Harold Walder said. "We are so excited to take this next step to get the treatment into the clinic."
For more information: www.immunolight.com
November 13, 2025 
